CN114927223A - Evaluation model and method for differentiated thyroid cancer after total resection - Google Patents

Abstract

The invention discloses a full-resection postoperative evaluation model and method for differentiated thyroid cancer, wherein the model comprises the following steps: a data module for storing patient information, the patient information comprising: pathology information, serum data, and image data; a death risk assessment module for assessing a death risk based on the pathological information; a recurrence risk assessment module for assessing a recurrence risk based on the pathology information, the serum data, and the image data; the evaluation module before the postoperative iodine treatment is used for judging the curative effect of the operation based on the serum data and the image data; a real-time dynamic assessment module for assessing a patient treatment efficacy based on the pathology information, the serum data, and the image data. The model of the invention can definitely judge the operation curative effect and the treatment curative effect, and gives a patient and a definite judgment standard so as to ensure the patient to definitely determine the self condition and be convenient for a doctor to pertinently select a treatment scheme to treat the patient.

Description

Evaluation model and method for differentiated thyroid cancer after total resection

Technical Field

The invention relates to the field of medicine, in particular to a postoperative evaluation model and method for differentiated thyroid cancer.

Background

The incidence rate of thyroid Cancer is getting more and more attention year by year, and according to data estimation of International Agency for Research on Cancer (IARC) in 2018, the incidence rate of thyroid Cancer is about 6.7/10 ten thousand worldwide, and the annual new increase of cases in China reaches 19 thousand. Differentiated Thyroid Cancer (DTC) originates in thyroid follicular cells, is the most common type of thyroid cancer, mainly includes papillary carcinoma, follicular carcinoma, Hu · rthle cell carcinoma and poorly differentiated thyroid carcinoma, and accounts for more than 95% of the total thyroid carcinoma. At present, a plurality of methods for treating thyroid cancer exist, but there is no clear guidance on judging the curative effect and the treatment effect of the operation.

Disclosure of Invention

Objects of the invention

The invention aims to provide a model and a method for evaluating differentiated thyroid cancer after total resection, which can definitely judge the curative effect and the curative effect of the operation.

(II) technical scheme

To solve the above problems, a first aspect of the present invention provides a full-resection evaluation model for differentiated thyroid cancer, comprising: a data module for storing patient information, the patient information comprising: pathology information, serum data, and image data; the death risk assessment module is used for acquiring the pathological information and assessing the death risk based on the pathological information; a recurrence risk assessment module for acquiring the pathological information, the serum data and the image data, and assessing a recurrence risk based on the pathological information, the serum data and the image data; a pre-operative iodine therapy evaluation module for acquiring the serum data and the image data and determining the operative effect based on the serum data and the image data; a real-time dynamic assessment module for assessing a patient treatment efficacy based on obtaining the pathology information, the serum data, and the image data, and based on the pathology information, the serum data, and the image data.

Further, the evaluation model for thyroid cancer differentiation after total resection further comprises: and the follow-up visit duration module is used for acquiring the information of the patient and obtaining the follow-up visit duration after treatment based on the information of the patient.

Further, the serum data includes: tg, TSH, TgAb and sTg data.

Further, the image data includes: ultrasound data, CT data, DxWBS data, RxWBS data, and bone visualization data.

Further, the pre-operative iodine therapy assessment module comprises: a first determination unit configured to derive a first determination condition based on the serum data; a first evaluation module that evaluates a surgical efficacy based on the first determination condition and the image data; wherein the serum data comprises: first bleeding data were TgAb1, Tg1, sTg1 and TSH 1; secondary bleeding data were TgAb2, Tg2, sTg2 and TSH 2;

the first determination condition includes the following A, B and C:

a: under the condition that TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

a1: TSH2< (2 ng/mL) and Tg0<0.2 ng/mL;

a2: TSH2>30ng/mL and Tg2<1.0 ng/mL;

b: one of the following two conditions is satisfied:

B1. under the conditions that TgAb1 is less than 115IU/mL and TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

b11: TSH1< ═ 2ng/mL and 0.2ng/mL < ═ Tg1< ═ 1 ng/mL;

b12: TSH2>30ng/mL and 1ng/mL < Tg2< 10 ng/mL;

b2: under the condition that TgAb1> -115 IU/mL or TgAb2> -115 IU/mL, TgAb2< TgAb1 (1+ 20%);

c: one of the following two conditions is satisfied:

c1: under the conditions of TgAb1<115IU/mL and TgAb2<115IU/mL, one of the following two conditions is further satisfied:

c11: TSH2< (2 ng/mL) and Tg2>1.0 ng/mL;

c12: TSH2>30ng/mL and Tg2>10 ng/mL;

c2: under the condition that TgAb1> -115 IU/mL or TgAb2> -115 IU/mL, TgAb2< TgAb1 (1+ 20%) is satisfied.

Further, the first evaluation module is configured to: judging that the curative effect is satisfactory based on the first judgment condition A and the iconography; determining that the curative effect is not definite based on that the first determination condition is B and the iconography is positive; determining that the biochemical treatment effect is poor based on the first determination condition being C and the imaging-rule; based on the image data indicating a recurrence or metastasis, it is determined that the structural therapy is not good. .

Further, the real-time dynamic evaluation module includes: a second determination unit configured to derive a second determination condition based on the serum data and the image data; a second evaluation module for evaluating a patient treatment efficacy based on the second determination condition;

the second determination condition includes the following a to E:

a, serum data meet one of the following two conditions, and imaging-;

a1: TgAb <115IU/mL, and TSH < ═ 2ng/mL and Tg <0.2 ng/mL;

a2: TgAb <115IU/mL, and TSH >30ng/mL and Tg <1.0 ng/mL;

b, one of the following two conditions is satisfied;

b1, satisfies TgAb <115IU/mL, and is imageology-, and satisfies one of the following conditions, then satisfies condition B1:

b11, TSH 2ng/mL and 0.2ng/mL Tg1 ng/mL;

b12 TSH >30ng/mL and 1ng/mL < Tg <10 ng/mL;

b2, meeting TgAb > -115 IU/mL, and TgAb2< TgAb1 (1+ 20%) and imageology-;

c, one of the following two conditions is satisfied;

c1, satisfies TgAb <115IU/mL, and is imagewise-, and satisfies one of the following conditions, then satisfies condition C1:

c11: TSH < ═ 2ng/mL and Tg > -1.0 ng/mL;

c12: TSH >30ng/mL and Tg > -10 ng/mL;

c2 TgAb > -115 IU/mL, and TgAb2> -TgAb 1 (1+ 20%) and imageology-;

d, at any level in serology; imaging to confirm the presence of disease;

e, the imaging results are ambiguous.

Further, the second evaluation module is to: judging that the curative effect is satisfactory based on the second judgment condition A; judging that the curative effect is not exact based on the second judgment condition B; if the second judgment condition is C, judging that the biochemical treatment effect is poor; determining that the structural treatment effect is poor based on the second determination condition being D; and judging that the imaging is not clear based on the second judgment condition being E.

Further, the risk of relapse includes high risk, intermediate risk, and low risk;

wherein, accord with any one of following condition, be high-risk:

the tumor can be seen to invade the surrounding tissues or organs visually;

failure of the tumor to be completely resected;

the image data shows that the remote transfer exists;

serum data showed distant metastasis;

FTC is associated with extensive vascular invasion;

meeting any one of the following conditions, namely, being in medium risk;

under the microscope, the tumor is found to be invaded by soft tissues around the thyroid;

after primary iodine 131 treatment, RxWBS finds that the transfer focus outside the thyroid bed of the neck part takes iodine;

tumors are invasive histological subtypes;

PTC is associated with vascular invasion;

lymph node metastasis is found clinically or > 5 lymph node metastases are found in pathological examination;

low risk meeting any one of A, B, C and D below:

a, PTC with a pathological type of 1 and meeting all of the following conditions a1-a7 is at low risk:

a1: no local or distant metastasis;

a2: all macroscopic tumors were completely excised;

a3: the tumor does not invade surrounding tissues;

a4: tumors are not an aggressive histological subtype;

a5, if treated with iodine 131, RxWBS shows no abnormal radioactive iodine uptake outside thyroid bed for the first time;

a6: no vascular invasion;

a7: no lymph node metastasis is found clinically or less than 5 lymph node micrometastases are found in pathological examination

B, FV-PTC restricted to the thyroid gland;

c, highly differentiated FTC localized in the thyroid, with invasion of the envelope, with no or only microvascular invasion (< 4 lesions);

d, intrathyroid, unifocal or multifocal PTMC.

Further, the follow-up visit duration module comprises: a first duration unit for determining a follow-up duration when a first iodine 131 treatment has been made; a second duration unit for determining a follow-up duration when the iodine 131 treatment has not been performed.

A second aspect of the present invention provides a method for post-total resection evaluation of differentiated thyroid cancer, comprising: obtaining information of a patient, the information of the patient comprising: pathology information, serum data, and image data; assessing a risk of death based on the pathological information; assessing a risk of relapse based on the pathology information, the serum data, and the image data; determining the surgical efficacy based on the serum data and the image data; assessing a patient treatment efficacy based on the pathology information, the serum data, and the image data. .

(III) advantageous effects

The technical scheme of the invention has the following beneficial technical effects:

the evaluation model of the invention can definitely judge the operation curative effect and the treatment curative effect through the data module, the death risk evaluation module, the recurrence risk evaluation module, the postoperative iodine pre-treatment evaluation module and the real-time dynamic evaluation module, and can definitely provide a definite judgment standard for patients so that the patients can definitely determine the self condition and doctors can conveniently and pointedly select a treatment scheme to treat the patients.

Drawings

FIG. 1 is a schematic structural view of a post-total-resection evaluation model of differentiated thyroid cancer according to a first embodiment of the present invention;

fig. 2 is a flowchart of a method for post-total-resection evaluation of differentiated thyroid cancer according to a second embodiment of the present invention.

Reference numerals

100: a data module; 200: a mortality risk assessment module; 300: a recurrence risk assessment module; 400: a post-operative pre-iodine treatment evaluation module; 500: a real-time dynamic evaluation module; 600: and a follow-up visit duration module.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the accompanying drawings in combination with the embodiments. It is to be understood that these descriptions are only illustrative and are not intended to limit the scope of the present invention. Moreover, in the following description, descriptions of well-known structures and techniques are omitted so as to not unnecessarily obscure the concepts of the present invention.

Some english abbreviations are first explained:

TgAb: represents an anti-thyroglobulin antibody;

tg: represents a thyroglobulin antibody;

sTg: represents a stimulatory thyroglobulin antibody; i.e., the value of Tg at TSH >30 ng/mL.

TSH: represents thyroid stimulating hormone.

First embodiment

Fig. 1 is a schematic structural view of a post-total-resection evaluation model for differentiated thyroid cancer according to a first embodiment of the present invention.

As shown in fig. 1, the present embodiment provides a post-total-resection evaluation model for differentiated thyroid cancer, including: a data module 100 for storing information of a patient, the information of the patient including: pathology information, serum data, and image data; a death risk assessment module 200 for assessing a death risk based on the pathology information; a recurrence risk assessment module 300 for assessing a recurrence risk based on the pathology information, the serum data, and the image data; a pre-postoperative iodine therapy assessment module 400 for based on serum data and image data; a real-time dynamic assessment module 500 for assessing based on the pathology information, the serum data, and the image data after iodine treatment. The evaluation model of the embodiment can definitely judge the operation curative effect and the treatment curative effect through the data module 100, the death risk evaluation module 200, the recurrence risk evaluation module 300, the pre-operation iodine treatment evaluation module 400 and the real-time dynamic evaluation module 500, and can definitely judge a definite judgment standard for a patient so as to definitely determine the self condition of the patient and conveniently enable a doctor to pointedly select a treatment scheme to treat the patient.

The serum data at least include: tg, TSH, TgAb and sTg data.

The image data at least includes: ultrasound data, CT data, and DxWBS data.

The pathological information at least comprises: the number of lesions and nails remaining.

The serum data specifically includes serum data of postoperative levothyroxine tablets, including: tg0, TSH0, TgAb0, and sTg0 data; and, serum data from two pre-iodine-131 treatments bleeds, including: tg1, TSH1, TgAb1 and sTg1 data and Tg2, TSH2, TgAb2 and sTg2 data.

Wherein, in the order of treatment, the patient information may include:

basic information, including: patient ID number, name, sex, age of diagnosis and date of birth;

first operative anterior nail function comprising: ID number, name, number of operations, time, thyroid stimulating hormone (TSH: unit: uIU/ML), thyroglobulin (Tg: unit: ng/ML, thyroglobulin antibody (TgAb: unit: IU/ML), thyroid stimulating hormone receptor antibody (TRAb: unit: IU/L), antithyroid peroxidase antibody (A-TPO: unit: IU/ML) of the patient, this first operation, i.e., the differentiated thyroid cancer total resection;

pathology information, including: ID number, name, operation times, operation time, operation mode, operation incisional boundary, pathological type, pathological subtype, differentiation degree, whether the postoperative pathology indicates Hashimoto's thyroiditis or other primary tumors of thyroiditis unilateral or bilateral, primary focus maximum diameter, capsule involvement, blood vessel invasion number, invasion significance around farthest inclination and range, multifocal property and multifocal number of patients, whether lymph node clearing, lymph node clearing number, lymph clearing number total, lymph node metastasis number total metastatic lymph node maximum diameter, distant metastasis site, distant metastasis description, immunohistochemistry Ki-67 (unit:%), immunohistochemistry VEGF, TERT mutation, Braf mutation, K-ras mutation, H-ras mutation, N-ras mutation, TP 53 mutation, RET, and immunohistochemistry EGFR;

post-operative arrest L-T4 anterior onycholysis comprising: ID number, name, number of surgeries, time of detection 1, thyroid stimulating hormone 1 (TSH: unit: uIU/Ml), thyroglobulin 1 (Tg: unit: ng/Ml), thyroglobulin antibody 1 (TgAb: unit: IU/Ml), thyroid stimulating hormone receptor antibody 1 (TRAb: unit: IU/L), time of detection 2, thyroid stimulating hormone 2 (TSH: unit: uIU/Ml), thyroglobulin 2 (Tg: unit: ng/Ml), thyroglobulin antibody 2 (TgAb: unit: IU/Ml) and thyroid stimulating hormone receptor antibody 2 (TRAb: unit: IU/L). Here, serum data from two tests are retained or more;

iodine 131 pre-treatment assessments, including: ID number, name, number of surgeries, number of iodine treatments performed in advance, imaging examination, manner of raising TSH, time to withdrawal L-T4, time to draw blood 1, thyroid stimulating hormone 1 (TSH: unit: uIU/Ml), thyroglobulin 1 (Tg: unit: ng/Ml), thyroglobulin antibody 1 (TgAb: unit: IU/Ml), thyroid stimulating hormone receptor antibody 1 (TRAb: unit: IU/L), time to draw blood 2, thyroid stimulating hormone 2 (TSH: unit: uIU/Ml), thyroglobulin 2 (Tg: unit: ng/Ml), thyroglobulin antibody 2 (TgAb: unit: IU/Ml) and thyroid stimulating hormone receptor antibody 2 (TRAb: unit: IU/L). Wherein, the imaging examination includes: cervical B-ultrasound, thoracic CT results, other exam (e.g., PET/CT, MIBI, etc.), other exam descriptions, diagnostic iodine-131 whole body imaging (DxWBS), and diagnostic iodine-131 whole body imaging other metastasis descriptions;

iodine 131 treatment comprising: patient ID number, name, number of surgeries, number of iodine treatments, date of treatment, treatment dose, imaging exam-post-treatment iodine-131 whole body imaging (RxWBS), and post-treatment iodine-131 whole body imaging (RxWBS) other metastasis descriptions;

follow-up after iodine 131 treatment, comprising: patient ID number, name, number of surgeries, number of iodine treatments, number of visits, date of blood draw, thyroid stimulating hormone (TSH: unit: uIU/Ml), thyroglobulin (Tg: unit: ng/Ml), thyroglobulin antibodies (TgAb: unit: IU/Ml), thyroid stimulating hormone receptor antibodies (TRAb: unit: IU/L) and imaging examinations. Wherein, the imaging examination includes: cervical B-mode ultrasound, thoracic CT, DxWBS other metastasis description, other examination (e.g., PET/CT, MIBI, etc.), and other examination description of imaging examination.

As a result, it includes: patient ID number, name, tumor TNM staging-T, tumor TNM staging-N, tumor TNM staging-M, STAGE (8TH), recurrence risk stratification, post-operative state assessment, real-time dynamic assessment, and length of follow-up (month) after initial treatment.

The following values will be explained first:

the operation mode is as follows: 0 indicates no further thyroid surgery (including lymph node dissection)

1 denotes a unilateral cut

2, indicates a near/full cut

3, for residual thyroidectomy;

cutting the edge through the operation: 0 indicates negative

1, indicates positive;

the type of pathology: 0, no evidence of primary tumor

1, PTC (papillary carcinoma)

2, FTC (follicular carcinoma)

Not 3, represents MTC (medullary carcinoma)

4, ATC (undifferentiated carcinoma);

pathological subtype: 1.1, stands for classic

1.2, indicating follicular subtype

1.3 denotes a solid/beam/island type

1.4, represents a high cell subtype

1.5, represents a subtype of diffuse sclerosis

1.6, for clear cell type

1.7, represents a columnar cell subtype

1.8 denotes a wrapped form

1.9 indicates a mulberry type with a sieve shape

1.10, indicates a spike type (micro nipple/loss of adhesion)

1.11 indicates an eosinophil type

1.12, indicates a fusiform cell type

1.13, indicates nodular fasciitis type

1.14, representing the Warthin-like type;

b ultrasonic of the neck: 0 indicates negative (no apparent abnormality)

1 represents the residue of onychomycosis

2 denotes residual disease

3, indicates a suspicious metastatic lymph node

4, represents a metastatic lymph node

5, indicates that benign or malignant could not be determined;

chest CT: 0 indicates no specific change or benign lesions were observed

1 indicates pulmonary metastasis, which is more reduced or diminished

2, it indicates lung metastasis, no obvious change earlier

3 indicates pulmonary metastasis, more advanced increase or enlargement

4, indicating lung lesion, benign and malignant could not be determined;

other examinations (e.g., PET/CT, MIBI, etc.): 0, negative (no signs of overt metastasis);

1 denotes residual thyroid gland

2 indicates lymph node metastasis

3, indicates lung metastasis

4 indicates bone metastasis

5, denote other transfers (other please add descriptions by itself);

diagnostic iodine-131 whole body imaging (DxWBS): not found thyroid or metastasis (or minimal residual thyroid)

1, denotes residual thyroid gland only

2, denotes a metastatic lymph node

3, indicates lung metastasis

4 indicates bone metastasis

5, indicates (other metastases, such as brain metastases, liver metastases, etc.);

imaging exam-post-treatment iodine-131 whole body imaging (RxWBS): 0 means no residual thyroid gland or metastasis (very small amount)

1, denotes residual thyroid gland only

2, denotes a metastatic lymph node

3, indicates lung metastasis

4, indicates bone metastasis

5, stands for others;

there will be 3+4 in the values, 2+3 similarly, with a convention of using a "+" sign split;

farthest invasion and extent: 0 indicates in the thyroid gland

1 denotes thyroid gland capsule/extracapsular fibroadipose tissue

2 denotes a banded muscle

3, denotes the subcutaneous soft tissue, larynx, trachea, oesophagus or recurrent laryngeal nerve

4, meaning involvement of the anterior fascia, or surrounding the carotid artery or mediastinal vessels;

whether or not the vessel is invaded: 0 indicates no

1, if a plurality of foci invade the blood vessel

Degree of differentiation: 1 indicates low differentiation

2 denotes the differentiation into middle fractions

High differentiation is indicated by 3.

Before describing the logic of each module in detail, a value rule is explained:

1. in the model of the invention, the sign of ">" and "<" related to all Tg, TSH and TgAb can be directly removed in the background logic judgment, and the judgment is carried out by using numbers.

2. In the model of the present invention, all data of the "operation and pathological condition table" are used, and values are taken according to the following rules (all the following superimposed value-taking rules are only used for the operation mode of 2 and the previous operations) when the operation is performed for a plurality of times:

if the operation mode has 0+2 similar data, dividing the operation mode according to the plus sign, and respectively judging;

(1) the operation time is as follows: setting the operation time of the operation mode 2 as A, and taking A;

(2) surgical margin, whether the envelope is compromised, whether the vessel is invaded, multifocal, immunohistochemical VEGF, TERT mutations, Braf mutations: as long as 1 is present, the value is 1;

(3) the type of pathology: firstly, all data are taken, and whether non-0 data exist or not is judged; if the non-0 data does not exist, judging whether the non-0 data exists or not, if so, taking 0, and if not, considering that the data is missing; if the data is not 0, judging whether the data are all the same, if so, taking the value, and if not, adding the values in different ways; for example: if there are 3 pieces of data, null, 0 and 0, then 0 is taken; there are 3 pieces of data, empty, 1 and 1, take 1; there are 3 pieces of data, 0, 1 and 2, take 1+ 2; the subsequent logic is strictly matched, the pathological type is 1, and if the pathological type is 1+2, the pathological type is not met.

(4) Pathological subtypes: when judging, taking the value of the previous time, and judging whether any one exists or not according to 1.1-1.15 and logic;

(5) degree of differentiation: when judging, according to 1-3, taking the value of the minimum number;

(6) primary tumors were single-bilateral: as long as 2 is present, the value is 2;

(7) maximum primary focus diameter, invasion vascular focus number, farthest invasion range, peripheral invasion significance, multiple focus number, immunohistochemical Ki-67: performing multiple operations, and taking the maximum value;

(8) distant metastasis site: taking the value according to the actual value. When the value is 0, M0 is judged, and when the value is 1, 2 and 3, M1 is judged, the most serious value is selected, namely 0<1<2< 3. If a person has 2 pieces of data, the value of the operation mode which is 0, and the value of the operation mode which is 1, then 1 is taken;

(9) lymph node clearance count, total clearance, total metastasis count, total metastasis:

when N stages in the TNM stages are judged, according to operation data of each time and according to TNM stage rules, N stages are respectively calculated, and finally, according to serious values, the results are seriously compared according to the rules: 0< N1a < N1< N1 b; for example, if the final data N results in N1a and N1b, then N1b is taken.

When determining the risk of relapse, the surgery mode is the sum of the corresponding values of all the multiple surgeries 2 and 2 before.

In one embodiment, this embodiment details the pre-post-operative iodine therapy assessment module 400.

Only the remaining nails were counted as negative in imaging (i.e., imaging-).

The evaluation before iodine treatment mainly depends on imaging and serology data for judgment, the obtained data is partial data of 'evaluation before iodine 131 treatment' or 'postoperation stopping L-T4 anterior onychomycosis', and the value-taking rule is as follows:

(1) if the evaluation before iodine 131 treatment and the evaluation before postoperative L-T4 forenail function have data, taking the data of the evaluation before iodine 131 treatment; if one part has no data, the value is taken according to the data part; if "both parts have no data missing.

(2) When part of data of 'evaluation before iodine 131 treatment' is taken, the judgment conditions are based on sTg and TgAb; in this section, the value of "number of treatment with iodine to be performed beforehand" is 0 or 1.

(3) When partial data of 'postoperation stopping L-T4 anterior onycholysis' is taken, the judgment condition is based on Tg and TgAb, values are directly taken here, and theoretically, only one data exists in the partial data.

(4) Firstly, judging the TgAb trend, and taking data of two times of blood drawing time when the TgAb is used no matter taking partial data of 'evaluation before iodine 131 treatment' or 'postoperation stopping on L-T4 forenail work'; the trend rule is shown below

(5) When TgAb is negative, sTg or Tg condition is judged, and whether partial data of 'evaluation before iodine 131 treatment' or 'stopping L-T4 previous first work after total excision' are taken, only data Tg2 and TSH2 of the second blood drawing time are taken as required data.

Judging TgAb trend: the judgment is only needed when the TgAb is positive, namely the TgAb is more than or equal to 115IU/mL, and if the TgAb is less than 115IU/mL, the judgment trend is not needed. Whether the data of the first blood drawing and the second blood drawing are evaluated before iodine 131 treatment or the data of the first blood drawing and the second blood drawing of the part of 'postoperation stopping L-T4 prematurity', the TgAb is judged to be positive if one of the data is more than or equal to 115 IU/mL. TgAb trend is judged if positive.

If both the first blood drawing and the second blood drawing are less than 115IU/mL, the determination is made under the following determination conditions.

Among them, the first blood draw data were TgAb1, Tg1, sTg1, and TSH 1. The second bleeding data were TgAb2, Tg2, sTg2 and TSH 2. Further, the condition for determining the stability or decrease of TgAb was TgAb2< TgAb1 (1+ 20%); the TgAb rise determination condition was TgAb2> -TgAb 1 (1+ 20%).

Wherein, imaging-represents: no evidence of imaging confirmation or functional disease exists, i.e. no lesions are reported by imaging, all imaging-is judged-. I.e. chest CT is 0, and neck B-ultrasound is (0 or 1) and the other exams are (0 or 1) and DxWBS is (0 or 1 or 2 or 1+ 2).

The decision conditions were classified based on patient serum data as A, B and C, 3 cases:

a: under the condition that TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

(1) (TSH2< (2 ng/mL) and Tg0<0.2ng/mL)

(2) (TSH2>30ng/mL and Tg2<1.0 ng/mL).

B: one of the following two (1 or 2) conditions is satisfied:

1. under the conditions that TgAb1 is less than 115IU/mL and TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

(1) TSH1< ═ 2ng/mL and 0.2ng/mL < ═ Tg1< ═ 1 ng/mL;

(2) TSH2>30ng/mL and 1ng/mL Tg2< ═ 10 ng/mL.

2. Under the condition that TgAb1> -115 IU/mL or TgAb2> -115 IU/mL, TgAb2< TgAb1 (1+ 20%) is satisfied.

C: one of the following two (1 or 2) conditions is satisfied:

1. under the conditions of TgAb1<115IU/mL and TgAb2<115IU/mL, one of the following two conditions is further satisfied:

(1) TSH2< (2 ng/mL) and Tg2>1.0 ng/mL;

(2) TSH2>30ng/mL and Tg2>10 ng/mL.

2. Under the condition that TgAb1> -115 IU/mL or TgAb2> -115 IU/mL, TgAb2< TgAb1 (1+ 20%) is satisfied.

Then, the curative effect of the operation is judged based on the judgment condition of the serum data and the image data.

Satisfactory curative effect (hereinafter referred to as P-ER), uncertain curative effect (hereinafter referred to as P-IDR), poor biochemical treatment effect (hereinafter referred to as P-BIR), poor structural treatment effect (hereinafter referred to as P-SIR) or ambiguous imaging (hereinafter referred to as P-UCC):

1.P-ER

satisfy the above A and satisfy the judgment of satisfactory curative effect by the imaging method.

2.P-IDR

B above and the imaging-rule is not sure.

3.P-BIR

Satisfy C above and the imaging-rule determines that the biochemical treatment is not good.

4.P-SIR

When the serology is at any level and the imaging is clear to relapse or transfer, the structural curative effect is judged to be poor;

that is, the image data satisfies any one of the following conditions:

(1) the neck B ultrasonic result is 2 or 4;

(2) the chest CT super result is 1-3;

(3) the other inspection results are any one of 2 to 5;

(4) DxWBS results are any of 3-5.

5.P-UCC

Determining that the imaging is ambiguous if the image data satisfies any one of the following conditions:

(1) the neck B ultrasonic result is 3 or 5;

(2) the chest CT super result is 4;

(3) the other examination results were 6.

In one embodiment, the present embodiment details the real-time kinematic assessment module 500, wherein the real-time kinematic assessment module 500 assesses the efficacy of patient treatment based on the pathology information, the serum data, and the image data.

Wherein the therapeutic effect comprises: satisfactory curative effect (hereinafter abbreviated as ER), uncertain curative effect (hereinafter abbreviated as IDR), poor biochemical treatment effect (hereinafter abbreviated as BIR), poor structural treatment effect (hereinafter abbreviated as SIR) or unclear imaging (hereinafter abbreviated as UCC).

The value rule of this embodiment is:

comparing the second blood drawing date of the part of evaluation before iodine 131 treatment and the blood drawing date of the part of follow-up diagnosis after iodine 31 treatment to obtain the latest date, and taking the relevant data in the follow-up diagnosis after iodine 131 treatment if the latest date is the blood drawing date of the follow-up diagnosis after iodine 131 treatment; if the date of the second blood drawing is the date, the value is taken as the relevant data in the evaluation before the iodine 131 treatment.

If the dates are incomplete, the completion is 1 day or 1 month and 1 day by default, and if 2020, the completion is as follows by default: 2020-01-01, if 2020-08, default is: 2020-08-01, if the same date data appears, the data is recorded as the latest data according to the recording sequence.

If the data is missing, the data is continuously traced back according to the reverse time sequence until the data is available; if the result is not evaluated, the data are continuously traced back according to the reverse time sequence until the result is evaluated. Here only traced back in the current table.

Wherein, if the data of the 'iconography-' does not exist at this time, the data need to be traced back; the evaluation before iodine 131 treatment part and follow-up diagnosis after iodine 131 treatment part sequentially trace back according to the iodine treatment times before the advance and the blood drawing date after the iodine 131 treatment until each of the 4 items (chest CT, neck B ultrasonic, other examinations and DxWBS) respectively has data; tracing the RxWBS of the iodine-131 treatment part, taking the treatment date as the latest data, and if no data exists at this time, tracing forwards; and sequentially tracing back according to the treatment date until the RxWBS has data.

If there is no data in the above 5 items (chest CT, neck B-mode, other examinations, DxWBS, RxWBS), the default is 0.

Wherein, the imaging comprises: there is no evidence of imaging confirmation or functional disease, i.e. no focus is reported by the image, no nail remains, the patient is normal, and all imaging is judged-. The method comprises the following specific steps:

chest CT is 0 and neck B-ultrasound is (0 or 1) and the other exams are (0 or 1) and DxWBS is (0 or 1 or 2 or 1+2) and (RxWBS is 0 or 1 or 2 or 1+2) (where 0 already contains no data).

Judging the treatment effect:

1.ER

values were taken from the "follow-up after iodine-131 treatment" or "assessment before iodine 131 treatment" partial data, where in case of "assessment before iodine 131 treatment", TgAb is TgAb2 for the second draw and TSH and Tg are TSH2 and Tg2 for the second draw.

The serum data satisfied one of the following conditions, and the imaging-was judged to be satisfactory.

(1) TgAb <115IU/mL, and TSH < ═ 2ng/mL and Tg <0.2 ng/mL;

(2) TgAb <115IU/mL, and TSH >30ng/mL and Tg <1.0 ng/mL;

2.IDR

values were taken from the "follow-up after iodine-131 treatment" or "assessment before iodine-131 treatment" partial data.

If one of the following conditions A or B is satisfied, the therapeutic effect is determined to be not definite.

A, satisfies TgAb <115IU/mL (if it is part of the data "assessment before treatment with iodine 131", here the conditions are TgAb1<115IU/mL and TgAb2<115IU/mL), and imaging-, and satisfies one of the following conditions, then condition A is satisfied:

(1) TSH 2ng/mL and 0.2ng/mL Tg <1 ng/mL;

(2) TSH >30ng/mL and 1ng/mL < Tg <10 ng/mL;

b, TgAb > -115 IU/mL (if part of the data "assessment before iodine 131 treatment", here the conditions are: TgAb1> -115 IU/mL or TgAb2> -115 IU/mL) and TgAb2< TgAb1 (1+ 20%) and imaging-.

Wherein TgAb2< TgAb1 (1+ 20%) TgAb1 and TgAb2 in this partial condition, in the case of the "assessment before treatment with iodine 131" portion, TgAb1 and TgAb2 are the original TgAb1 and TgAb2 in the data column, and in the case of the "follow-up after treatment with iodine-131" TgAb1 refers to the TgAb advanced one time in time, and TgAb2 is this time TgAb.

3.BIR

Values are obtained from partial data of 'follow-up diagnosis after iodine-131 treatment' or partial data of 'evaluation before iodine-131 treatment'.

If one of the following conditions A or B is satisfied, the biochemical treatment effect is determined to be poor.

A, satisfies TgAb <115IU/mL (if it is "iodine 131 pre-treatment assessment" partial data, here conditions: TgAb1<115IU/mL and TgAb2<115IU/mL), and imaging-, and satisfies one of the following conditions, then condition A is satisfied:

(1) TSH < ═ 2ng/mL and Tg > -1.0 ng/mL;

(2) TSH >30ng/mL and Tg > -10 ng/mL.

B, TgAb > -115 IU/mL (if part of the data "assessment before treatment with iodine 131", here the conditions are: TgAb1> -115 IU/mL or TgAb2> -115 IU/mL), and TgAb2> -TgAb 1 (1+ 20%) and imaging-.

TgAb2> -TgAb 1 (1+ 20%) TgAb1 and TgAb2 in this partial condition, in the case of the "assessment before treatment with iodine 131" part, TgAb1 and TgAb2 are the original TgAb1 and TgAb2 in the data column, and in the case of the "follow-up after treatment with iodine 131", TgAb1 refers to the TgAb pushed once before time, and TgAb2 is this time TgAb.

4.SIR

Serology at any level; imaging confirmed the presence of the disease.

If one of the following conditions is satisfied, the structural treatment effect is determined to be poor:

(1) the neck B ultrasonic result is 2 or 4;

(2) the chest CT super result is 1-3;

(3) the other inspection results are any one of 2 to 5;

(4) DxWBS results were any of 3-5;

(5) RxWBS results were any of 3-5.

5.UCC

Determining that the imaging is ambiguous if the image data satisfies any one of the following conditions:

(1) the neck B ultrasonic result is 3 or 5;

(2) the chest CT super result is 4;

(3) the other examination results were 6.

In one embodiment, the present embodiment specifically describes a mortality risk assessment module 200 for assessing the risk of mortality of a patient based on the pathology information. The present example uses a TNM staging system to assess the risk of mortality for the patient.

First, the TNM staging system is currently the most internationally used tumor staging system.

TNM staging system:

t ("T" is the initial letter of the word "Tumor" in the context of tumors) refers to the condition of the primary Tumor focus, and is indicated by T1-T4 in sequence as the Tumor volume increases and the affected area of adjacent tissues increases.

2, N ("N" is the initials of the term "Node" in the name of lymph Node) refers to a regional lymph Node (regional lymph Node) involvement. Lymph nodes, when not affected, are designated N0. Along with the increase of the lymph node involvement degree and range, sequentially represented by N1-N3,

3, M ("M" is the initials of the word metastasis ") refers to distant metastases (usually blood-way metastases), represented by M0 for those who do not have distant metastases and M1 for those who have distant metastases.

On the basis of the above, a specific stage (stage) is marked by using a combination (grouping) of three indexes of TNM.

The method comprises the following steps: stage I, stage II, stage III, stage IVA and stage IVB.

TNM-T:T0、T1a、T1b、T2、T3a、T3b、T4a、T4b；

TNM-N：Nx、N0、N1、N1a、N1b；

TNM-M：M0、M1

TNM is derived from the "surgical and pathological conditions" section, with the following rules:

1. is judged as stage I

Determining as stage I if any of the following conditions is satisfied

(1) Age <55 and M ═ 0;

(2) age > 55 and (T-1 a or T-1 b or T-2) and (N-0 or N-X) and M-0;

2. determination as stage II

Stage II is judged if any of the following conditions is satisfied

(1) Age <55 and M ═ 1;

(2) the diagnosis age > 55 and (T-1 a or T-1 b or T-2) and (N-1 or N-1 a or N-1 b) and M-0;

(3) age > 55 and (T ═ 3a or T ═ 3b) and (N ═ 0 or N ═ 1a or N ═ 1b) and M ═ 0;

3. determination as stage III

If age > 55 and T4 a (N-0 or N-1 a or N-1 b) and M0 are determined, stage III is determined.

4. Stage IVA

If age > 55 and T4 b (N-0 or N-1 a or N-1 b) and M0 are determined, then the phase iva is determined.

5. Stage IV B

If the diagnosis age > is 55 and M is 1, it is determined as ivb stage.

Wherein, the TNM staging is according to the following table

TABLE 1 staging of differentiated thyroid cancer TNM (8th edition)

The TNM staging criteria were as follows:

in one embodiment, this embodiment generally describes a risk of recurrence assessment module 300 for assessing risk of recurrence based on the pathology information, the serum data, and the image data. In particular to the stratification of the recurrence risk.

The method comprises the following specific steps:

the risk of relapse is stratified into: high-level, medium-risk and low-risk.

Surgery and pathological conditions: thirdly, taking values according to the rule 2 in the value specification in the logic algorithm;

iodine 131 pre-treatment assessment: the number of "advanced iodine therapy" was taken as 1, and the data corresponds to the second blood drawing time.

Carrying out logic judgment from high danger to low danger in sequence, and if the high danger is judged, continuously judging whether the high danger is medium danger or low danger; if the low-risk condition is judged, the low-risk condition is not judged continuously.

1. Determined as high risk

Any one of the following conditions is met, namely the high risk:

1) the tumor is visible to the naked eye to invade surrounding tissues or organs, specifically, the surrounding invasion is visible to the naked eye and invades the peri-capsular tissue of the thyroid furthest. Further specifically, the peripheral invasion resolution in surgical and pathological cases is 2 and the farthest invasion range is 1 or 2 or 3 or 4.

2) Tumors failed to be completely resected with residual remaining in the procedure, specifically, the requirements were interpreted as: cervical ultrasound reports residual lesions. Further specifically, neck B-mode was 2 in the pre-treatment assessment with iodine 131.

3) Distant metastasis, specifically, distant metastasis such as DxWBS, breast CT, bone imaging, and the like, reporting lung metastasis, bone metastasis, and the like; distant metastasis does not include lymph nodes; other imaging examinations found metastasis of lung, bone, etc. are also the judgment condition. More specifically, any one of the following conditions is satisfied in the pre-treatment evaluation of iodine 131:

(1) the chest CT result is 1-3;

(2) the other inspection results are any one of 3 to 5;

(3) iodine-131 systemic imaging (DxWBS) resulted in either 3-5.

4) Following total thyroidectomy, serum Tg levels were still high suggesting distant metastasis, specifically, stimulatory Tg greater than 47.1 ng/mL. More specifically, any one of the following conditions is satisfied in the pre-treatment evaluation of iodine 131:

(1) TSH1 is greater than 30uIU/mL and Tg1>47.1 ng/mL;

(2) TSH2 is greater than 30uIU/mL and Tg2>47.1 ng/mL.

5) FTC is associated with widespread vascular invasion (> 4 lesions), specifically the type of pathology is FTC, >4 lesions invading the blood vessels. Further specifically, the type of pathology is 2 and whether the vessel is invaded is 1 and the number of foci of invasion is >4 in surgery and pathological cases.

2. Is judged to be in danger

The medium risk is determined by meeting any one of the following conditions:

1) perithyroid soft tissue invasion of the tumor was found microscopically, specifically peri-and farthest invasion of the peri-thyroid tissue. Further specifically, the peripheral invasion significance is 1 and the most distal invasion range is 1 or 2 or 3 or 4 in surgical and pathological situations.

2) RxWBS after initial 131I treatment was found to have cervical extrathyroid metastases to take up iodine, specifically, RxWBS after initial iodine 131 treatment was found to have lymph node metastases. Further specifically, in the iodine 131 treatment table, the iodine treatment number is 1, and the iodine-131 systemic imaging (RxWBS) after treatment is equal to 2 or 1+ 2.

3) Tumors are invasive histological subtypes (e.g., high cell type, columnar cell type, solid subtype, diffuse sclerosis type, boot-pin type, squamous cell differentiation). In particular, the pathological subtype (1.3 or 1.4 or 1.5 or 1.7 or 1.10 or 1.15). Further specifically, it is satisfied that any one of the pathological subtypes exists in the surgical and pathological conditions: 1.3 or 1.4 or 1.5 or 1.7 or 1.10 or 1.15.

4) PTC IS associated with vascular invasion, specifically, the type of pathology in surgical and pathological cases IS 1 and whether the vessel IS invaded (IS _ BLOOD _ vein) IS 1.

5) Lymph node metastasis was found clinically or > 5 lymph node metastases were found in pathological examination, specifically, tumor TNM staging-N in surgical and pathological cases was: 1 or 1a or 1b, and the number of lymph node metastases totals > 5.

3. Judged as low risk

Low risk in compliance with either of A, B, C and D:

a, PTC with a pathological type of 1 and meeting all of the following conditions 1) -7) is low risk:

1) no local or distant metastases, in particular, as judged by reports of diagnostic imaging DxWBS, post-treatment imaging RxWBS, cervical ultrasound, breast CT, bone imaging, and the like. Further specifically, in the pre-treatment assessment of iodine 131: chest CT is 0 and neck B-ultrasound is 0 or 1 and other exams are 0 or 1 and diagnostic iodine-131 whole body imaging (DxWBS) is 0 or 1; and in iodine 131 treatment: iodine-131 systemic imaging (RxWBS) ═ 0 or-1 after treatment.

2) All macroscopic tumors were completely resected, specifically, unless the surgical margin was pathologically reported positive. Further specifically, the surgical margin is empty or equal to 0 in surgical and pathological situations.

3) The tumor does not invade the surrounding tissue, in particular, the primary focus. Further specifically, the most aggressive and range in surgical and pathological conditions is 0.

4) Tumors are not invasive histological subtypes (e.g., high cell type, columnar cell type, solid subtype, diffuse sclerosis type, boot-spike type, squamous cell differentiation, etc.), and specifically, pathological subtypes, conditions for judging pathological subtypes should be excluded from the above-mentioned invasive types. Further specifically, in surgical and pathological situations: no one of the pathological subtypes exists: 1.3 or 1.4 or 1.5 or 1.7 or 1.10 or 1.15.

5) Following treatment with 131I, the first RxWBS showed no abnormal radioiodine uptake outside the thyroid bed, specifically, imaging the RxWBS after the first treatment showed no local or distant metastasis, leaving only the nail. Further specifically, in the iodine 131 treatment information table (iodine 131_ treat), after-treatment iodine-131 whole body imaging (RxWBS) ═ 0 or ═ 1, and the iodine treatment number is 1.

6) No vascular invasion, particularly in surgical and pathological conditions: whether or not a blood vessel is invaded is 0.

7) Lymph node metastasis is not found clinically, or less than 5 lymph node micrometastases are found in pathological examination. Specifically, any one of the following 2 conditions is satisfied in the surgical and pathological conditions:

(1) tumor TNM staging-N (TNM _ N) is: 0;

(2) (tumor TNM stage-N (TNM _ N) is: 1 or 1a or 1b) and (total number of lymph node metastases is ═ 5).

B, FV-PTC confined to the inside of the thyroid gland, specifically, the pathological type, tumor without peripheral invasion, FV-PTC is follicular papillary carcinoma and therefore should be of the pathological type 1 and pathological subtype 1.2 follicular subtype, further specifically, the most distant invasion and range in surgery and pathological cases is 0 and the pathological type 1 and pathological subtype 1.2.

C, highly differentiated FTC localized in the thyroid, with invasion of the envelope, with no vascular invasion or only microvascular invasion (< 4 lesions), in particular, with no peri-invasion of the tumor, with a pathological type of FTC, highly differentiated, vascular invasion <4 lesions or no vascular invasion. Further specifically, all of the following conditions are met in surgical and pathological situations:

(1) maximum penetration range of 0

(2) Pathological type 2

(3) Degree of differentiation of 3

(4) Whether a vessel is invaded is 0 or (whether a vessel is invaded is 1 and the number of foci of the vessel is invaded is < 4).

And D, PTMC limited to thyroid gland, single focus or multiple focuses, specifically, the diameter of the tumor is less than or equal to 1cm, the pathological type is PTC, and the tumor is free from peripheral invasion. Further specifically, the type of pathology in surgery and pathological cases is 1 and the largest diameter of the primary focus is ≦ 1cm and the farthest extent is 0.

In one embodiment, the present embodiment describes a follow-up duration module 600, the follow-up duration module 600 configured to derive a post-treatment follow-up duration based on patient information.

The follow-up duration module 600 includes a first duration unit, configured to determine the follow-up duration when the first iodine 131 treatment has been performed, specifically, (1) in the iodine 131 treatment in the patient information, data whose iodine treatment frequency is equal to 1 exists, and the treatment date data of the current data is taken; (2) in the follow-up diagnosis after iodine 131 treatment, if data exist, the date of the last blood drawing is taken, the treatment date in the step (1) is subtracted, and the follow-up visit duration is calculated.

The follow-up duration module 600 includes a second duration unit, configured to determine the follow-up duration when no iodine 131 treatment is performed, specifically, (1) only data with iodine treatment times equal to 0 exists in the iodine 131 treatment table; (2) the operation mode in the operation and pathological condition table is equal to 2, if the operation mode exists, the operation time of the data is taken; (3) and (3) in the follow-up table after iodine 131 treatment, if data exist, the date of the last blood drawing is taken, the operation time in the step (2) is subtracted, and the follow-up visit duration is calculated.

For example, the follow-up duration unit is "month", and the calculation rule:

subtracting the previous date from the next date, subtracting according to the whole month, dividing the rest days by 30 days when the month is less than 1 month, taking 2 decimal places, and finally combining to obtain the product.

If the first treatment date is "2020-08-12" and the last follow-up blood drawing date is "2020-12-05", the calculation is as follows:

(1) because 12-05 is less than 12-12, the whole month is calculated by subtracting 08-12 from 11-12, namely 11-8, and is 3 months;

(2) the remaining days are 23 days calculated by subtracting 11-12 from 12-05, and 2 decimal places are divided by 30 to be 0.77 month;

(3) the final follow-up period was 3+0.77 to 3.77 months.

Second embodiment

As shown in fig. 2, the present embodiment provides a method for post-total resection evaluation of differentiated thyroid cancer, comprising: obtaining information of a patient, the information of the patient comprising: pathology information, serum data, and image data; assessing a risk of death based on the pathological information; assessing a risk of relapse based on the pathology information, the serum data, and the image data; determining the surgical efficacy based on the serum data and the image data; assessing a patient treatment efficacy based on the pathology information, the serum data, and the image data. The evaluation method of the embodiment can definitely judge the operation curative effect and the treatment curative effect, and can definitely judge a definite judgment standard for a patient so as to ensure the self condition of the patient and be convenient for a doctor to pointedly select a treatment scheme to treat the patient.

In an embodiment, the evaluation method further comprises: deriving a post-treatment follow-up length based on the patient's information.

The same parts of this embodiment as those of the previous embodiment will not be described herein.

It should be understood that the above-described embodiments of the present invention are merely illustrative of or explaining the principles of the invention and are not to be construed as limiting the invention. Therefore, any modifications, equivalents, improvements and the like which are made without departing from the spirit and scope of the present invention shall be included in the protection scope of the present invention. Further, it is intended that the appended claims cover all such variations and modifications as fall within the scope and boundary of the appended claims, or the equivalents of such scope and boundary.

Claims (11)

1. A post-pancreatectomy evaluation model for differentiated thyroid cancer comprising:

a data module for storing patient information, the patient information comprising: pathology information, serum data, and image data;

the death risk assessment module is used for acquiring the pathological information and assessing the death risk based on the pathological information;

a recurrence risk assessment module for acquiring the pathological information, the serum data and the image data, and assessing a recurrence risk based on the pathological information, the serum data and the image data;

a pre-operative iodine therapy evaluation module for acquiring the serum data and the image data and determining the operative effect based on the serum data and the image data;

a real-time dynamic assessment module for assessing a patient treatment efficacy based on obtaining the pathology information, the serum data, and the image data, and based on the pathology information, the serum data, and the image data.

2. The post-total-resection evaluation model for differentiated thyroid cancer according to claim 1, further comprising:

and the follow-up visit duration module is used for acquiring the information of the patient and obtaining the follow-up visit duration after treatment based on the information of the patient.

3. The post-total-resection evaluation model for differentiated thyroid cancer according to claim 1, wherein the serum data comprises: tg, TSH, TgAb and sTg data.

4. The post-pancreatectomy evaluation model for differentiated thyroid cancer according to claim 1, wherein the image data comprises: ultrasound data, CT data, DxWBS data, RxWBS data, and bone visualization data.

5. The model for post-total resection evaluation of differentiated thyroid cancer according to claim 1, wherein the module for pre-post-operative iodine therapy evaluation comprises:

a first determination unit configured to derive a first determination condition based on the serum data;

a first evaluation module for evaluating a surgical effect based on the first determination condition and the image data;

wherein the serum data comprises: first bleeding data were TgAb1, Tg1, sTg1 and TSH 1; the second bleeding data were TgAb2, Tg2, sTg2 and TSH 2;

the first determination condition includes the following A, B and C:

a: under the condition that TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

a1: TSH2< (2 ng/mL) and Tg0<0.2 ng/mL;

a2: TSH2>30ng/mL and Tg2<1.0 ng/mL;

b: one of the following two conditions is satisfied:

B1. under the conditions that TgAb1 is less than 115IU/mL and TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

b11: TSH1< ═ 2ng/mL and 0.2ng/mL < ═ Tg1< ═ 1 ng/mL;

b12: TSH2>30ng/mL and 1ng/mL < Tg2< 10 ng/mL;

b2: under the condition that TgAb1> -115 IU/mL or TgAb2> -115 IU/mL, TgAb2< TgAb1 (1+ 20%);

c: one of the following two conditions is satisfied:

c1: under the conditions that TgAb1 is less than 115IU/mL and TgAb2 is less than 115IU/mL, one of the following two conditions is further met:

c11: TSH2< (2 ng/mL) and Tg2>1.0 ng/mL;

c12: TSH2>30ng/mL and Tg2>10 ng/mL;

c2: under the condition that TgAb1> -115 IU/mL or TgAb2> -115 IU/mL, TgAb2< TgAb1 (1+ 20%) is satisfied.

6. The post-total excision assessment model for differentiated thyroid cancer according to claim 5, wherein said first assessment module is used for:

judging that the curative effect is satisfactory based on the first judgment condition A and imaging;

judging that the curative effect is not definite based on the first judgment condition B and imaging;

judging that the biochemical treatment effect is poor based on the first judgment condition C and imaging;

based on the image data indicating a recurrence or metastasis, a structural therapy is determined to be poor.

7. The post-pancreatectomy evaluation model for differentiated thyroid cancer according to claim 1, wherein the real-time dynamic evaluation module comprises:

a second determination unit configured to derive a second determination condition based on the serum data and the image data;

a second evaluation module for evaluating a patient treatment efficacy based on the second determination condition;

the second determination condition includes the following a to E:

a, serum data meets one of the following two conditions, and imaging-;

a1: TgAb <115IU/mL, and TSH < ═ 2ng/mL and Tg <0.2 ng/mL;

a2: TgAb <115IU/mL, and TSH >30ng/mL and Tg <1.0 ng/mL;

b, one of the following two conditions is satisfied;

b1, satisfies TgAb <115IU/mL, and is imagewise-, and satisfies one of the following conditions, then satisfies condition B1:

b11 TSH 2ng/mL and 0.2ng/mL Tg1 ng/mL;

b12 TSH >30ng/mL and 1ng/mL < Tg <10 ng/mL;

b2, satisfying TgAb > -115 IU/mL, and TgAb2< TgAb1 (1+ 20%) and imageology-;

c, one of the following two conditions is met;

c1, satisfies TgAb <115IU/mL, and is imagewise-, and satisfies one of the following conditions, then satisfies condition C1:

c11: TSH < ═ 2ng/mL and Tg > -1.0 ng/mL;

c12: TSH >30ng/mL and Tg > -10 ng/mL;

c2 TgAb > -115 IU/mL, and TgAb2> -TgAb 1 (1+ 20%) and imageology-;

d, any level of serology; imaging to confirm the presence of disease;

e, the imaging results are ambiguous.

8. The post-total-resection evaluation model for differentiated thyroid cancer according to claim 7,

the second evaluation module is to:

judging that the curative effect is satisfactory based on the second judgment condition A;

judging that the curative effect is not exact based on the second judgment condition B;

if the second judgment condition is C, judging that the biochemical treatment effect is poor;

determining that the structural treatment effect is poor based on the second determination condition being D;

and judging that the iconography is not clear based on the second judgment condition being E.

9. The model for the evaluation of differentiated thyroid cancer after total resection according to claim 1, wherein the risk of recurrence comprises high risk, intermediate risk and low risk;

wherein, accord with any one of following condition, be high-risk:

the tumor can be seen to invade the surrounding tissues or organs by naked eyes;

failure of the tumor to be completely resected;

the image data shows that the remote transfer exists;

serum data showed distant metastasis;

FTC is associated with extensive vascular invasion;

meeting any one of the following conditions, namely, being in medium risk;

under the microscope, the tumor is found to be invaded by soft tissues around the thyroid;

after primary iodine 131 treatment, RxWBS finds that the transfer focus outside the thyroid bed of the neck part takes iodine;

tumors are invasive histological subtypes;

PTC is associated with vascular invasion;

lymph node metastasis is found clinically or > 5 lymph node metastases are found in pathological examination;

low risk in compliance with either of A, B, C and D:

a, PTC with a pathological type of 1 and meeting all of the following conditions a1-a7 is at low risk:

a1: no local or distant metastasis;

a2: all macroscopic tumors were completely excised;

a3: the tumor does not invade surrounding tissues;

a4: tumors are not an aggressive histological subtype;

a5, if treated with iodine 131, RxWBS shows no abnormal radioactive iodine uptake outside thyroid bed for the first time;

a6: no vessel invasion;

a7: no lymph node metastasis is found clinically or less than 5 lymph node micrometastases are found in pathological examination

B, FV-PTC restricted to intrathyroid;

c, highly differentiated FTC localized in the thyroid, with invasion of the envelope, with no or only microvascular invasion (< 4 lesions);

d, intrathyroid, unifocal or multifocal PTMC.

10. The post-pancreatectomy evaluation model for differentiated thyroid cancer according to claim 2, wherein the follow-up duration module comprises:

a first duration unit for determining a follow-up duration when a first iodine 131 treatment has been made;

a second duration unit for determining a follow-up duration when the iodine 131 treatment has not been performed.

11. A method for post-pancreatectomy evaluation of differentiated thyroid cancer, comprising:

obtaining information of a patient, the information of the patient comprising: pathology information, serum data, and image data;

assessing a risk of death based on the pathological information;

assessing a risk of relapse based on the pathology information, the serum data, and the image data;

determining the surgical effect based on the serum data and the image data;

assessing a patient treatment efficacy based on the pathology information, the serum data, and the image data.

Images